Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer.
Patricia M SheeanSandra Gomez-PerezCara JoycePaula O'ConnorMonica BojkoAmber SmithVasilios VasilopoulosRuta RaoJoy SclambergPatricia RobinsonPublished in: Breast cancer research and treatment (2021)
Targeted interventions initiated within the first year of diagnosis to preserve or improve SM quality seem warranted for women with ER-MBC.